SURF [NASD]
Surface Oncology, Inc.
Index- P/E- EPS (ttm)-1.27 Insider Own0.80% Shs Outstand48.61M Perf Week-15.87%
Market Cap98.07M Forward P/E- EPS next Y-1.86 Insider Trans-35.67% Shs Float36.65M Perf Month-15.05%
Income-56.70M PEG- EPS next Q-0.46 Inst Own63.50% Short Float7.24% Perf Quarter-47.45%
Sales31.10M P/S3.15 EPS this Y-214.00% Inst Trans25.88% Short Ratio3.49 Perf Half Y-68.86%
Book/sh3.02 P/B0.58 EPS next Y-44.00% ROA-28.30% Target Price11.40 Perf Year-79.07%
Cash/sh2.68 P/C0.65 EPS next 5Y- ROE-41.60% 52W Range1.83 - 9.57 Perf YTD-63.39%
Dividend- P/FCF- EPS past 5Y-21.80% ROI-52.80% 52W High-81.71% Beta1.65
Dividend %- Quick Ratio9.40 Sales past 5Y-16.50% Gross Margin- 52W Low-4.37% ATR0.19
Employees67 Current Ratio9.40 Sales Q/Q-99.80% Oper. Margin- RSI (14)34.85 Volatility8.09% 9.98%
OptionableYes Debt/Eq0.17 EPS Q/Q133.90% Profit Margin- Rel Volume0.87 Prev Close1.87
ShortableYes LT Debt/Eq0.17 EarningsMay 09 BMO Payout- Avg Volume760.86K Price1.75
Recom1.50 SMA20-16.27% SMA50-28.86% SMA200-63.39% Volume658,692 Change-6.42%
May-18-21Initiated BTIG Research Buy $17
Sep-04-20Initiated H.C. Wainwright Buy $11
Aug-28-20Initiated Wedbush Outperform $12
Sep-19-18Initiated Robert W. Baird Outperform
May-14-18Initiated Goldman Neutral $17
May-14-18Initiated Evercore ISI Outperform $26
May-17-22 04:30PM  
May-11-22 06:28AM  
May-09-22 07:10AM  
May-06-22 04:30PM  
08:50AM  
Apr-27-22 04:15PM  
Apr-21-22 04:05PM  
Apr-14-22 07:30AM  
Apr-11-22 09:47AM  
Apr-08-22 04:01PM  
Apr-01-22 04:43PM  
Mar-31-22 07:30AM  
Mar-15-22 07:30AM  
Mar-02-22 08:42AM  
07:10AM  
Mar-01-22 03:00PM  
08:55AM  
Feb-28-22 04:30PM  
Feb-24-22 07:55AM  
Feb-22-22 08:05AM  
Feb-10-22 07:00AM  
Jan-10-22 01:49PM  
Dec-15-21 07:05AM  
Dec-06-21 09:30AM  
Dec-03-21 07:00AM  
Dec-02-21 07:00AM  
Dec-01-21 07:00AM  
Nov-29-21 06:44AM  
Nov-26-21 06:57AM  
Nov-09-21 08:10AM  
Nov-08-21 03:44PM  
07:00AM  
Nov-04-21 07:10AM  
Nov-02-21 07:00AM  
Oct-12-21 11:21AM  
Oct-04-21 10:56AM  
07:00AM  
Sep-20-21 05:44PM  
Sep-13-21 09:02AM  
Aug-23-21 12:03PM  
Aug-05-21 07:10AM  
Jul-08-21 07:00AM  
07:00AM  
Jun-04-21 10:17AM  
10:04AM  
07:05AM  
07:00AM  
May-28-21 06:20AM  
May-24-21 08:53AM  
May-18-21 08:48AM  
May-16-21 06:20AM  
May-05-21 06:45AM  
Apr-28-21 04:05PM  
Apr-27-21 07:00AM  
Apr-19-21 07:00AM  
Apr-09-21 07:53AM  
Apr-08-21 07:32AM  
Mar-31-21 11:12AM  
Mar-30-21 06:11PM  
04:30PM  
Mar-23-21 11:47PM  
Mar-18-21 08:00AM  
Mar-17-21 08:01AM  
Mar-10-21 04:35PM  
Mar-09-21 08:25AM  
07:01AM  
07:00AM  
06:43AM  
Mar-05-21 08:48AM  
Mar-02-21 12:30PM  
Feb-24-21 07:00AM  
Feb-23-21 07:25AM  
Feb-22-21 06:21AM  
Feb-11-21 07:00AM  
Jan-19-21 03:25PM  
Jan-13-21 08:39AM  
Jan-11-21 06:00AM  
Dec-22-20 12:20PM  
04:37AM  
Dec-17-20 03:35PM  
08:10AM  
06:55AM  
Dec-14-20 07:07AM  
Dec-07-20 08:29AM  
Nov-25-20 07:00AM  
Nov-15-20 08:39AM  
06:57AM  
Nov-13-20 07:05AM  
Nov-11-20 07:00AM  
Nov-10-20 06:20AM  
Nov-09-20 04:25PM  
09:00AM  
Nov-05-20 09:43AM  
Oct-26-20 04:05PM  
Oct-20-20 01:03PM  
Oct-19-20 12:32PM  
Oct-12-20 03:41PM  
Sep-16-20 05:05PM  
Sep-15-20 07:23AM  
Sep-11-20 03:00PM  
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FEES JESSICAChief Financial OfficerJul 21Sale6.1019,854121,10979,329Jan 14 08:30 PM
ONEILL ALISONChief Medical OfficerJul 21Sale6.1014,80990,33530,191Jan 14 08:30 PM
Nogelo Liisa IChief Legal OfficerJul 21Sale6.1026,325160,58253,675Jan 14 08:30 PM
ROSS ROBERT W.Chief Executive OfficerJul 21Sale6.1033,500204,35054,500Jan 14 08:30 PM
Palombella Vito J.Chief Scientific OfficerJul 21Sale6.1026,325160,58253,675Jan 14 08:30 PM
Goater JeffDirectorJul 21Sale6.10127,778779,446129,222Jan 14 08:30 PM
Goater JeffDirectorJun 11Option Exercise4.1410,27342,530272,273Jun 11 08:30 PM
Goater JeffDirectorJun 11Sale7.6115,273116,226257,000Jun 11 08:30 PM
Goater JeffDirectorJun 10Option Exercise4.14234,727971,770496,727Jun 11 08:30 PM
Goater JeffDirectorJun 10Sale7.66234,7271,798,619262,000Jun 11 08:30 PM